Increasing Cancers Drive Global Anti-CD20 Monoclonal Antibodies Market

Increasing incidence of cancers is the major growth driver of global Anti-CD20 antibodies market.  Key players are acquiring new drugs and new technologies. W.H.O., FEAT, and others along with the government are spreading awareness about cancers which is anticipated to facilitate market growth.

On 8th Dec 2020, Roche presented new data from its bispecific antibody across different types of blood cancer. These antibodies work by binding to two different targets, on two different cells, simultaneously: one on the surface of cancer cells and one on the surface of immune cells called T-cells. This dual targeting approach activates a patient’s existing T-cells to engage and eliminate target cancer cells, offering an innovative approach for the treatment of blood cancers.

The Global Anti-CD20 Monoclonal Antibodies Market accounted for $6.21 billion in 2019 and is estimated to be $14.5 billion by 2029 and is anticipated to register a CAGR of 8.9%. Anti-CD20 monoclonal antibodies are used for the treatment of B-cell malignancies due to its advantage as they enhance killing activities and improves CD-20 levels on cell surface to increase the activity of lymphoma therapy. Due to increased demand for these antibodies, companies are emphasizing on developing next generation anti-CD20 monoclonal antibodies.

The report “Global Anti-CD20 Monoclonal Antibodies Market, By Product Type (First Generation Anti-CD20 Monoclonal Antibodies, Second Generation Anti-CD20 Monoclonal Antibodies and Third Generation Anti-CD20 Monoclonal Antibodies), By End-User (Hospitals, Clinics, Academic & Research Institutions and Contract Research Organization (CRO’s)), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) – Market Trends, Analysis, and Forecast till 2030”

Key Highlights:

  • On 8th Dec 2020, Roche presented new data from its bispecific antibody across different types of blood cancer. These antibodies work by binding to two different targets, on two different cells, simultaneously: one on the surface of cancer cells and one on the surface of immune cells called T-cells. This dual targeting approach activates a patient’s existing T-cells to engage and eliminate target cancer cells, offering an innovative approach for the treatment of blood cancers including non-Hodgkin lymphoma (NHL) and multiple myeloma (MM); diseases where treatment options are currently limited, and resistance to, or relapse following, treatment is common. These bispecific antibodies are just one of the novel ‘off-the-shelf’ technologies Roche is exploring, in its quest to improve patient outcomes.

Increasing incidence of cancers is the major growth driver of global Anti-CD20 antibodies market. The key players are coming with new drugs and new technologies by acquiring the other companies. Various organizations such as the W.H.O., FEAT, and others along with the government are spreading awareness about cancers which is anticipated to facilitate market growth in the forecast period.

To know the upcoming trends and insights prevalent in this market, click the link

Key Market Insights from the report:

Increasing incidence of cancers is the major growth driver of global Anti-CD20 antibodies market.

The Global Ati-CD20 Monoclonal Antibodies Market accounted for $6.21 billion in 2019 and is estimated to be $14.5 billion by 2029 and is anticipated to register a CAGR of 8.9%. The Global Anti-CD20 Monoclonal Antibodies Market is segmented based on the product type, end-user, and region.

  • On the basis of product type, the Global Anti-CD20 Monoclonal Antibodies Market is segmented into First Generation Anti-CD20 Monoclonal Antibodies, Second Generation Anti-CD20 Monoclonal Antibodies, and Third Generation Anti-CD20 Monoclonal Antibodies.
  • Based on end-user, the target market is segmented into hospitals, clinics, academic & research institutions and contract research organizations (CRO’s).
  • By region, the Global Anti-CD20 Monoclonal Antibodies Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is the worldwide leader in the Anti-CD20 Monoclonal Antibodies market in terms of revenue, due to the developed healthcare system and health awareness among people.

Competitive Landscape:

The key players operating in the Global Anti-CD20 Monoclonal Antibodies Market include Biogen, Inc., Genentech, Inc. (F. Hoffmann-La Roche AG), Genmab A/S, Immunomedics, Inc., Novartis AG, Spectrum Pharmaceuticals, Inc., Bio-Rad Laboratories, Inc., and LFB Biotechnologies S.A.

Get Report

Santosh M.

I am digital marketer in prophecy market insights.
https://www.prophecymarketinsights.com/